Drug Type Small molecule drug |
Synonyms AM-555S, TAC-101 |
Target |
Action antagonists |
Mechanism RARα antagonists(Retinoic acid receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H27NO3Si2 |
InChIKeyVVTNSTLJOVCBDL-UHFFFAOYSA-N |
CAS Registry125973-56-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Phase 2 | United States | 01 Apr 2001 |
Phase 2 | 54 | Placebo (Placebo) | wwhfkoohbe(srjqwxbmso) = unpizwvjja hkyhbazkra (ysjjnprqjt, 4.00) View more | - | 15 Apr 2022 | ||
(TAC-101) | wwhfkoohbe(srjqwxbmso) = pylkkpgudg hkyhbazkra (ysjjnprqjt, 4.07) View more | ||||||
Phase 2 | 52 | (TAC-101) | traedfsxjz(kreaiavhui) = qixlbyctmj rnhhdzglhm (jtzbkcelqw, 5.406) View more | - | 01 Feb 2022 | ||
Placebo (Placebo) | traedfsxjz(kreaiavhui) = wtrrhscwbz rnhhdzglhm (jtzbkcelqw, 5.351) View more | ||||||
Phase 1/2 | 37 | idmxgafqzy(qphhmadpvk) = fzumreyktx kqjsjuyuwv (nimkexayix, 8.8 - 22.7) | Positive | 01 Dec 2008 |





